1057 completed, 339 terminated, 254 recruiting, 213 unknown. 2234 Phase 2, 607 Phase 1, 76 Phase 3.
Follow Hemorrhagic Disorders: new trials by email Literature Review of Hemorrhagic Disorders trials Research Report on Hemorrhagic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Excyte Biopharma Ltd | 64 | 2027-12-01 | 2026-11-06 |
| Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 120 | 2027-08-01 | 2026-08-20 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-11-02 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-10-30 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 38 | 2026-12-01 | 2026-07-24 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
Showing 20 of 2234. Sign in to see all of them.
Multiple Myeloma (1584) · Neoplasms, Plasma Cell (276) · Lymphoma (255) · Lymphoma, Non-Hodgkin (254) · Waldenstrom Macroglobulinemia (253) · Leukemia, Lymphocytic, Chronic, B-Cell (240) · Recurrence (208) · Lymphoma, Follicular (201) · Lymphoma, B-Cell, Marginal Zone (197) · Hodgkin Disease (194) · Lymphoma, Mantle-Cell (181) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (179) · Leukemia (171) · Purpura, Thrombocytopenic, Idiopathic (168) · Leukemia, Myeloid, Acute (157)
Hemic and Lymphatic Diseases (2234) · Hematologic Diseases (2187) · Immune System Diseases (1968) · Cardiovascular Diseases (1865) · Vascular Diseases (1863) · Hemostatic Disorders (1825) · Neoplasms by Histologic Type (1789) · Immunoproliferative Disorders (1785) · Blood Protein Disorders (1769) · Neoplasms (1769) · Lymphoproliferative Disorders (1761) · Paraproteinemias (1761) · Neoplasms, Plasma Cell (1499) · Pathological Conditions, Signs and Symptoms (696)
Dexamethasone (531) · Bortezomib (273) · Lenalidomide (266) · Cyclophosphamide (245) · Melphalan (175) · Calcium Dobesilate (162) · daratumumab (135) · carfilzomib (113) · pomalidomide (112) · Rituximab (111) · fludarabine phosphate (101) · Peripheral Blood Stem Cell Transplantation (100) · Filgrastim (79) · Thalidomide (74) · Busulfan (72)
National Cancer Institute (NCI) (111) · Mayo Clinic (67) · Fred Hutchinson Cancer Center (61) · Institute of Hematology & Blood Diseases Hospital, China (49) · M.D. Anderson Cancer Center (49) · Memorial Sloan Kettering Cancer Center (47) · Peking University People's Hospital (40) · Dana-Farber Cancer Institute (33) · University of Arkansas (33) · GlaxoSmithKline (24) · Celgene (23) · Novartis Pharmaceuticals (22) · H. Lee Moffitt Cancer Center and Research Institute (21) · Janssen Research & Development, LLC (21) · Amgen (20)
United States (1384) · China (236) · France (180) · Germany (162) · Spain (157) · Canada (155) · United Kingdom (151) · Italy (149) · Australia (103) · South Korea (74) · Greece (72) · Netherlands (67) · Poland (66) · Japan (62) · Denmark (49)
Lei Zhang, MD (17) · Xiao-Hui Zhang, MD (10) · Brenda Sandmaier (9)
PMID 32499241, PMID 33357481, PMID 24802773, PMID 35285981, PMID 35549810, PMID 19216617, PMID 31221778, PMID 34182226, PMID 34398557, PMID 35075289, PMID 36408876, PMID 37934000, PMID 40156952, PMID 19179301, PMID 20661232, PMID 21403127, PMID 22430088, PMID 23470153, PMID 24802775, PMID 25628469, PMID 25824111, PMID 26181891, PMID 26308596, PMID 26690712, PMID 27307294, PMID 29025767, PMID 29224506, PMID 29567784, PMID 30536810, PMID 30957581, PMID 31433920, PMID 31527168, PMID 32107329, PMID 32463741, PMID 32470437, PMID 34465265, PMID 34826409, PMID 35132679, PMID 35857660, PMID 36853224, PMID 37022569, PMID 37270762, PMID 38649340, PMID 38826786, PMID 40000533, PMID 40386832, PMID 40471585, PMID 40501401, PMID 40674744, PMID 40750723
P30CA015083 (42), 2023 (39), U10CA180820 (38), 2017 (25), P30CA015704 (25), U24CA196172 (20), 2019 (18), 2018 (17), 2025 (15), 2014 (12), U10CA032102 (12), 2008 (11), 2015 (11), 2016 (11), P30CA006973 (11)